Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2015

View Archived Issues

Programmable probiotics as urinary diagnostic markers for liver metastases

Encouraging first-in-human data obtained with BI-836826 in CLL

Safety of tesevatinib assessed in a phase Ib trial

Allied-Bristol Life Sciences licenses intellectual property from Harvard

Vical releases topline data from phase I/II study of therapeutic genital herpes vaccine

Guselkumab and ustekinumab do not meet primary endpoint in rheumatoid arthritis trial

Gladius Pharmaceuticals raises funds to develop treatments for multidrug-resistant infections

First patient recruited in phase II study of preterm labor drug OBE-001

Soligenix collaborates with NORD and CLF on pivotal study of SGX-301 for CTCL

Group in Taiwan discloses B-Raf and C-RAF kinase inhibitors

Vertex Pharmaceuticals patents ATR kinase inhibitors

Boehringer Ingelheim patent describes kinase inhibitors

Pfizer opens enrollment in phase III trial of rivipansel in sickle cell disease

Potential new cancer treatments under study at Hangzhou Minsheng

Sanofi presents soluble epoxide hydrolase inhibitors

EMA grants orphan drug designation to AveXis' gene therapy treatment for SMA

CytoDyn to develop PRO-140 for GvHD

Biotest regains rights to tregalizumab after AbbVie opts out of agreement

ELND-005 does not meet primary endpoint in Alzheimer's disease trial

Vaccinex initiates phase II trial of VX-15/2503 in Huntington's disease

RaQualia regains dalbavancin rights in Japan

Agios initiates phase I trial of AG-881 in advanced solid tumors with IDH mutation

FDA clears IND for phase IIa study of T3D-959 in Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...